ADPT: Bull Flag detected on 27 Aug 2026

ADPT has formed a bull flag pattern following a significant advance, with the stock recovering sharply after announcing a plan in June 2026 to separate its MRD and Immune Medicine businesses. The pattern shows structure at 14.5/15, breakout strength at 11.2/13, and volume confirmation at 11.2/12, yielding an overall score of 85.9/98 with 73.53% win probability. Current price of $26.16 sits just 1.32% below the 52-week high, having surged 89% over three months. Resistance at $24.96 guards the breakout zone; invalidation occurs below $23.41 support. RSI at 64.24 suggests approaching overbought conditions, and volume is running 59% of the 20-day average—a potential concern for breakout sustainability.

ADPT reported Q2 2026 revenue of $71.6 million, up 21.5% year-over-year and above the $67.2 million estimate, with gross profit rising 25.7% to $51.4 million, reflecting improved product economics. The company raised full-year 2026 MRD revenue guidance to $268-$278 million and highlighted improving sequencing gross margins with ambitions to reach positive adjusted EBITDA and free cash flow by year-end 2026. However, the company posted a net loss of $39.8 million and ended the quarter with $169.9 million in cash against $490.0 million in liabilities. Insider trading shows concerning activity: 92 sales versus 0 purchases in the past 6 months, with Chief Scientific Officer Harlan Robins selling 1.5 million shares, and CEO Chad Robins also executing multiple sales. The pattern breakout is occurring within the Health Care sector's bullish regime (0.93 score), but broader market regime remains bearish at -0.21.

A successful bull flag breakout would drive ADPT through the $24.96 resistance level, targeting the conservative measured move of $27.02—representing approximately 3.3% upside from current levels. The stock has already demonstrated momentum capability with 90-day returns of 86.72%, but the current breakout requires volume confirmation above the 20-day average (currently at 59% of normal). Historical win probability of 73.53% supports execution, but invalidation triggers immediately below $23.41 support, where the flag foundation would collapse. The pattern strength relies on the MRD growth narrative holding and institutional buying returning to lift volume through the breakout.

Multiple headwinds threaten this setup. Heavy insider selling—92 sales to 0 purchases over six months with executives liquidating shares—signals reduced conviction among those closest to the business. The company requires MRD to grow into a self-funding franchise while managing persistent losses and cash burn, and the wider net loss keeps risk of future dilution and cost cuts front and center. Volume at 59% of 20-day average is notably weak for a breakout, creating vulnerability to a false move. Beta of 1.11 and 20-day volatility of 54.28% indicate elevated price swings. The broader market regime is bearish at -0.21, creating headwind resistance. Persistent company-wide losses and absence of Immune Medicine guidance keep the profitability timeline in focus. Next catalyst risk: any disappointing third-quarter update on MRD adoption could collapse the separation thesis and trigger sharp pullback toward $23.41.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.